RxDoctor Payments Data

Hind Neamah, MD

Internal Medicine · Richmond, TXNPI 1992291827

Payments from drug & device makers

$783in general payments, 2019–2025

Across 24 payments — averaging $32.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147
  • Gilead$122
  • Avanir Pharmaceuticals, Inc.$118
  • Janssen Scientific Affairs, LLC$100
  • Teva Pharmaceuticals USA, Inc.$96
  • Novartis$47
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$783 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,342
Medicare patients
12
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$25,003
JardianceEmpagliflozin20$18,182
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,494
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,413
Rosuvastatin Calcium28$1,267
Albuterol Sulfate HfaAlbuterol Sulfate22$761
Fluticasone Propionate44$530
Atorvastatin Calcium51$464
Losartan Potassium53$402
Metformin Hcl ErMetformin Hcl24$255
Alendronate Sodium11$210
Gabapentin12$209
Tamsulosin Hcl22$187
Omeprazole28$180
Amlodipine Besylate42$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$25,00318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Richmond

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →